Loading…
for educational and safety purposes
Cutamesine and PRE-084 both come up in the same conversations. Cutamesine: Cutamesine (SA4503) is a selective agonist of the sigma-1 receptor, an endoplasmic reticulum chaperone protein that modulates calcium signaling, mitochondrial function, and multiple neurotransmitter systems. PRE-084: PRE-084 is a synthetic, highly selective agonist of the sigma-1 receptor, an endoplasmic reticulum chaperone protein that modulates calcium signaling, neurotrophic factor expression, and cellular stress responses.
Cutamesine (SA4503) is a selective agonist of the sigma-1 receptor, an endoplasmic reticulum chaperone protein that modulates calcium signaling, mitochondrial function, and multiple neurotransmitter systems. Preclinical work shows that sigma-1 activation enhances neurite and axon outgrowth, protects neurons from oxidative and excitotoxic stress, and improves functional recovery when given days after experimental ischemic stroke, acting through neuroplasticity rather than acute neuroprotection. A phase 2 clinical trial in acute ischemic stroke found cutamesine safe and well tolerated, with a post hoc signal of greater neurological improvement among more severely affected patients. The same sigma-1 mechanism has drawn interest for depression, cognitive impairment, and motor neuron disease, and the carbon-11 labeled compound has been used as a PET radiotracer to quantify sigma-1 receptor occupancy. It has reached human testing but is not an approved drug.
PRE-084 is a synthetic, highly selective agonist of the sigma-1 receptor, an endoplasmic reticulum chaperone protein that modulates calcium signaling, neurotrophic factor expression, and cellular stress responses. It is used almost exclusively as a preclinical research tool, where it has produced neurorestorative effects in models of Parkinson disease [1], motor neuron survival in models of amyotrophic lateral sclerosis [2], and antidepressant and anti-amnesic activity [5]. A recurring theme across studies is upregulation of brain-derived neurotrophic factor (BDNF) and downstream trophic pathways [2][3][4].
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
Agonist
Selective agonist
Modulation
Modulation
Upregulation (indirect)
Activation (downstream)
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.